- Home
- SWIM vs SGP Comparison
SWIM vs SGP Comparison
Compare SWIM & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SWIM | SGP |
|---|---|---|
| Founded | 1956 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 657.5M | 650.9M |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | SWIM | SGP |
|---|---|---|
| Price | $7.34 | $26.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $6.75 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 918.6K | 73.2K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $545,912,000.00 | N/A |
| Revenue This Year | $10.95 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | $189.00 | ★ N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $4.64 | $17.06 |
| 52 Week High | $8.97 | $30.56 |
Technical Indicators
Market Signals| Indicator | SWIM | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 62.98 | 72.54 |
| Support Level | $6.13 | $25.25 |
| Resistance Level | $7.33 | $27.23 |
| Average True Range (ATR) | 0.34 | 1.36 |
| MACD | 0.16 | 0.28 |
| Stochastic Oscillator | 79.03 | 100.00 |
Price Performance
Historical ComparisonAbout SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. The company derives a majority of its revenue from the United States.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.